Brief: Entera Bio Presents Dose Proportional Absorption And Correlation To BMD Clinical Response Data From Its Phase 2 Study Of EB613 In Post-Menopausal Osteoporosis Patients At The ASBMR 2022 Annual Meeting
12/09/2022 11:31
Sept 12 (Reuters) - Entera Bio Ltd 5DT.F :
* ENTERA BIO PRESENTS DOSE PROPORTIONAL ABSORPTION AND
CORRELATION
TO BMD CLINICAL RESPONSE DATA FROM ITS PHASE 2 STUDY OF EB613 IN
POST-MENOPAUSAL OSTEOPOROSIS PATIENTS AT THE ASBMR 2022 ANNUAL
MEETING
Source text for Eikon: ID:nGNXQ0rjN
Further company coverage: 5DT.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Entera Bio
See all newsBrief: Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., As Chief Medical Officer Ahead Of Planned Eb613 Phase 3 Initiation
Corrected: Israel's Entera Bio Q2 net loss widens
NASDAQ RESUMED AT 10:02 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:57 AM
Brief: Entera Bio Announces Pricing Of Oversubscribed $275 Million Private Placement